Odyssey Therapeutics Inc.
ODTX | NASDAQ
$19.00
-$0.54 (-2.76%)
Nov 2, 2026, 10:42 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Cash & Equivalents | 82.03M | 35.72M |
Short-Term Investments | 228.54M | 140.03M |
Long-Term Investments | 122.49M | n/a |
Other Long-Term Assets | 3.79M | 5.26M |
Receivables | n/a | n/a |
Inventory | n/a | n/a |
Other Current Assets | 10.89M | 9.35M |
Total Current Assets | 321.46M | 185.1M |
Property-Plant & Equipment | 21.92M | 24.48M |
Goodwill & Intangibles | 14.19M | 14.23M |
Total Long-Term Assets | 162.39M | 43.97M |
Total Assets | 483.85M | 229.07M |
Account Payables | 7.67M | 8.22M |
Deferred Revenue | n/a | n/a |
Short-Term Debt | n/a | n/a |
Other Current Liabilities | 7.01M | 4.2M |
Total Current Liabilities | 28.3M | 22.21M |
Long-Term Debt | n/a | n/a |
Other Long-Term Liabilities | 14.97M | 709.8M |
Total Long-Term Liabilities | 34.33M | 730.55M |
Total Liabilities | 62.63M | 752.76M |
Total Debt | 24.83M | 26.13M |
Book Value | 421.22M | -523.69M |
Book Value Per Share | 13.91 | -11.10 |
Common Stock | 5K | n/a |
Retained Earnings | -659.19M | -606.4M |
Comprehensive Income | -505K | -147K |
Shareholders Equity | 421.22M | -523.69M |
Total Investments | 351.04M | 140.03M |
Add to Watchlist
Select watchlists to add or remove ODTX